Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I (Q45752944)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 1998

Language	Label	Description	Also known as
English	Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I	scientific article published in October 1998

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thierry Poynard

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

author name string

P Marcellin

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

S S Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

C Niederau

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

G S Minuk

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

G Ideo

6

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

V Bain

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

J Heathcote

8

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

S Zeuzem

9

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

C Trepo

10

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

J Albrecht

11

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

language of work or name

0 references

publication date

1 October 1998

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

352

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

9138

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

1426-1432

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907124-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(98)07124-4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9807989

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45752944&oldid=1770332506"